top of page

Clinical Drug Trial Studies //

​

 

Currently Open

​

1. Duet-UC (Guselkumab/Golimumab co-formulation)

  • Moderate to Severe UC

  • Combo therapy vs mono therapy vs placebo using guselkumab, golimumab, and Guselkumab/Golimumab co-formulation

  • Treatment experienced or intolerant to 1-2 classes of biologics such as Humira or Inflectra, Stelara, or Entyvio

  • 1:2:2:2:2:2 ( 10% placebo), 48-week treatment period, with extension up to 4 years of treatment

  • Monthly subcutaneous infusions (5 min), Week 24 change of dose or drug for nonresponders

 

 

2. Duet-CD (Guselkumab/Golimumab co-formulation) Crohn’s Disease

  • Moderate to Severe CD

  • Combo therapy vs mono therapy vs placebo using guselkumab, golimumab, and Guselkumab/Golimumab co-formulation

  • Treatment experienced or intolerant to 1-2 classes of biologics such as Humira or Inflectra, Stelara, or Entyvio

  • 1:2:2:2:2:2 ( 10% placebo), 48-week treatment period, with extension up to 4 years of treatment

  • Monthly subcutaneous infusions (5 min), Week 24 change of dose or drug for nonresponders

 

​

3. TEV-48574 CD and UC 

  • Moderate to Severe CD or UC

  • Dose-ranging mono therapy vs placebo using TEV-48574

  • Treatment experienced or intolerant to up to 2 classes of biologics, or never tried a biologic and have failed/been intolerant to steroids or immunomodulators like methotrexate or Azathioprine 

  • 1:1:1:1 (25% placebo), 14-week treatment period, with 44-week extension study available Spring 2024

  • Subcutaneous infusions every 2 weeks

 

​

4. IBS Probiotic B. longum (BL)

  • Diagnosis with IBS and self-reported psychological symptoms (no formal diagnosis)

  • Randomized 1:1 probiotic vs placebo for 14 weeks

  • Exclusion if diagnosed with celiac disease or use of drugs to control IBS symptoms

 

​

Coming Soon Drug Trials:

5. ABX464 UC *Spring 2024*

  • Moderate to Severe UC, Once Daily oral pill Obefazimod or placebo (25%) for 8-weeks, then 44-week open label.

  • Can have failed/been intolerant to steroids or immunomodulators like methotrexate or AZA, or failed any biologics

​

​

Currently Open Trials (non-drug):

​

1. SHARP Pancreas Divisum (in partnership with Dr. Dana Moffatt and Dr. Jean-Gerard Coneys)

  • Randomized trial of ERCP for treatment of recurrent acute pancreatitis

  • Must have had a documented pancreatitis attack within the last 2 years, plus one other attack prior

  • 1:1 randomization for ERCP or SHAM procedure

  • Must have the study procedure scheduled at HSC only

 

2. IBD Dysplasia surveillance

  • Scheduled Colonoscopy for surveillance only, UC or CD

  • IBD in remission, or mild-moderate flare, no active severe disease

  • 1:1 randomization targeted biopsies vs random biopsies for IBD Dysplasia surveillance

  • Must have a scope scheduled at HSC only

 

3. FMT in Pouchitis

  • Enema Fecal Transplant for active Pouchitis 

  • 1:1 randomization, 7-weeks Fecal Transplant or placebo, then 7 weeks open-label Fecal Transplant

  • Pouchoscopy is done at start, week 7 and week 14 of the study

  • Must have the scopes scheduled at HSC only

​

bottom of page